Freenome, Inc. (FRNM)
| Market Cap | 1.68B+47.3% |
| Revenue (ttm) | 35.41M |
| Net Income | -235.33M-123.4% |
| EPS | -2.04 |
| Shares Out | 107.45M |
| PE Ratio | n/a |
| Forward PE | -6.51 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,871 |
| Open | 15.85 |
| Previous Close | 16.03 |
| Day's Range | 15.18 - 16.18 |
| 52-Week Range | 9.95 - 17.50 |
| Beta | 0.45 |
| Analysts | none |
| Price Target | 18.00(+15.27%) |
| Earnings Date | n/a |
Insiders here have filed 15 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About FRNM
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
$FRNM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in FRNM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FRNM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FRNM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
FRNM Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Cash and investments held in Trust Account | $85.09M | 98.54% |
| Dividend income on the Trust Account | $487.56K | 0.56% |
| Cash | $437.37K | 0.51% |
| Investment income on the Trust Account | $339.77K | 0.39% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New FRNM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FRNM from public contracts
Source: USAspending.gov
FRNM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from FRNM’s recent data — informational, not investment advice